-
初诊的淋巴瘤患者是否存在骨髓浸润(bone marrow infiltration,BMI)对于疾病分期、治疗方案的选择及预后具有重要意义。BMI使分期上升至IV期,是疾病进展、预后较差的标志。目前,临床上主要依靠常规部位(髂前上棘、髂后上棘、胸骨)骨髓活检(bone marrow biopsy,BMB)诊断BMI。但是,BMB是一种有创性操作,存在抽样误差。而且,BMI病灶存在弥漫性和局灶性两种类型,对于不在常规穿刺部位的局灶性BMI病灶,BMB可能出现假阴性。这些缺陷限制了BMB的应用。全身MRI可以弥补BMB的不足,提高淋巴瘤BMI的检出率。全身MRI与PET/CT相辅相成,各具优势。另外,全身MRI对淋巴瘤BMI患者的预后可能具有预测价值。
全身MRI与PET/CT在淋巴瘤骨髓浸润诊断及预后中的作用
Function of whole-body MRI and PET/CT in the diagnosis and prognosis of lymphoma with bone marrow infiltration
-
摘要: 淋巴瘤是一种血液系统恶性肿瘤。淋巴瘤骨髓浸润(BMI)使疾病分期上升至IV期, 是疾病进展、预后较差的标志。常规部位的骨髓活检(BMB)具有创伤性, 且检出率低。PET/CT与全身MRI的出现, 丰富了BMI的检测手段。PET/CT与全身MRI对于淋巴瘤, 尤其是侵袭性淋巴瘤BMI均具有较高的检出率, 二者孰高孰低, 尚未定论。对于红骨髓、良性骨髓病变(炎症等)、淋巴瘤BMI病灶以及肿瘤治疗后骨髓的变化与骨髓残留或复发病灶, 全身MRI很难区分, 而PET/CT却可以很好地鉴别这些病灶。但是, PET/CT存在电离辐射; 对于惰性淋巴瘤的BMI, 超出PET/CT分辨率的病灶, 可能出现假阴性; 某些情况会限制PET/CT的使用, 包括18F-FDG生理性摄取量可能发生改变的正常组织、18F-FDG摄取相关性炎症、高血糖或高胰岛素血症导致的18F-FDG分布的改变、肿瘤患者治疗后出现的骨髓活化等。然而, 这些情况可以使用全身MRI。因此, 全身MRI和PET/CT相辅相成, 优势互补, 但二者均不能代替BMB。对于常规BMB阴性, 但影像学提示阳性的患者, 在影像学引导下进行BMB, 可以提高BMI的检出率。另外, 全身MRI阳性的淋巴瘤BMI患者与全身MRI阴性的淋巴瘤BMI患者相比, 前者预后可能较差。
-
关键词:
- 淋巴瘤 /
- 磁共振成像 /
- 正电子发射断层摄影术 /
- 体层摄影术, X线计算机 /
- 骨髓浸润 /
- 预后
Abstract: Lymphoma is a malignant tumor of the blood system.Bone marrow infiltration(BMI) advances the disease to stage IV and is a marker of disease progression and poor prognosis.Conventional bone marrow biopsy is a traumatic detection, and the rate is low.The emergence of PET/CT and whole-body MRI supplements the means of BMI detection.PET/CT and whole-body MRI both exhibit a high detection rate for lymphoma BMI, particularly for aggressive lymphoma BMI.However, both approaches to determine high and low is inconclusive, For red bone marrow, benign bone marrow lesions(inflammation and others), lymphoma BMI lesions, as well as bone marrow changes after tumor therapy and bone marrow residual or recurrent lesions, whole body MRI is difficult to distinguish.PET/CT can excellently identify these lesions.However, PET/CT uses ionizing radiation:false negative results can be present for inert lymphoma BMI lesions and lesions beyond the PET/CT resolution.Certain circumstances may limit the use of PET/CT, including normal tissue, whose 18F-FDG physiological uptake may change; inflammation, which is related to 18F-FDG uptake, changes in the distribution of 18F-FDG caused by high blood glucose or high blood insulin, bone marrow activation in tumor patients after treatment, and so on.In these cases, we can use whole-body MRI.Therefore, the two approaches are complementary.Neither PET/CT nor whole body MRI can replace BMB.BMB under the guidance of PET/CT or whole-body MRI considerably improves the detection rate of BMI for patients with negative BMB findings, but imaging findings are positive.In addition, whole-body MRI-positive patients may present poorer prognosis than whole-body MRI-negative patients. -
[1] Kwee TC, Kwee RM, Verdonck LF, et al.Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma[J].Br JHaematol, 2008, 141(1):60-68.DOI:10.1111/j.1365-2141.2008.07020.x. [2] Adams HJ, Kwee TC, Vermoolen MA, et al.Whole-body MRI for the detection of bone marrow involvement in lymphoma:prospective study in 116 patients and comparison with FDG-PET[J].Eur Radiol, 2013, 23(8):2271-2278.DOI:10.1007/s00330-013-2835-9. [3] Daldrup-Link HE, Henning T, Link TM.MR imaging of therapy-induced changes of bone marrow[J].Eur radiol, 2007, 17(3):743-761.DOI:10.1007/s00330-006-0404-1. [4] Nakanishi K, Kobayashi M, Nakaguchi K, et al.Whole-body MRI for detecting metastatic bone tumor:diagnostic value of diffusion-weighted images[J].Magn Reson Med Sci, 2007, 6(3):147-155.DOI:10.2463/mrms.6.147. [5] Takenaka D, Ohno Y, Matsumoto K, et al.Detection of bone metastases in non-small cell lung cancer patients:Comparison of whole-body diffusion-weighted imaging(DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy[J].J Magn Reson Imaging, 2009, 30(2):298-308.DOI; 10.1002/jmri.21858. doi: 10.1002/jmri.21858 [6] Adams HJA, Kwee TC, Vermoolen MA, et al.Whole-body MRI for the detection of bone marrow involvement in lymphoma:prospective study in 116 patients and comparison with FDG-PET[J].Eur radiol, 2013, 23(8):2271-2278.DOI:10.1007/s00330-013-2835-9. [7] Kwee TC, Fijnheer R, Ludwig I, et al.Whole-body magnetic resonace imaging, including diffusion-weighted imaging, for diagnosing bone marrow involvement in malignant lymphoma[J].Br J Haematol, 2010, 149(4):628-630.DOI:10.1111/j.1365-2141.2010.08093.x. [8] Brennan DD, Gleeson T, Coate LE, et al.A comparison of whole-body MRI and CT for the staging of lymphoma[J].AJR Am J Roentqenol, 2005, 185(3):711-716. doi: 10.2214/ajr.185.3.01850711 [9] 汤日杰, 桂思, 李建生, 等.18F-FDG PET/CT与大范围弥散磁共振成像评价非霍奇金淋巴瘤骨髓浸润的对比研究[J].中华血液学杂志, 2014, 35(3):231-235.DOI:10.3760/cma.j.issn.0253-2727.2014.03.011.
Tang RJ, Gui S, Li JS, et al.Comparison of 18F-FDG PET/CT and large-scale DWI for evaluation of non-Hodgkin lymphoma bone marrow infiltration[J].Chin J Hemorhed, 2014, 35(3):231-235. doi: 10.3760/cma.j.issn.0253-2727.2014.03.011[10] Kwee TC, Ludwig I, Uiterwaal CS, et al.ADC measurements in the evaluation of lymph nodes in patients with non-Hodgkin lymphom a:feasibility study[J].Magn Res Mater Phy, Biol Med, 2011, 24(1):1-8.DOI:10.1007/s10334-010-0226-7. [11] Kwee TC, de Klerk JM, Nievelstein RA.Imaging of bone marrow invo lvement in lymphoma:state of the art and future directions[J].Sci World J, 2011, 11:391-402.DOI:10.1100/tsw.2011.40. [12] Howe BM, Johnson GB, Wenger DE.Current concepts in MRI of focal and diffuse malignancy of bone marrow[J].Semin Musculoskelet Radiol.2013, 17(2):137-144.DOI:10.1055/s-0033-1343069. [13] Basu S, Torigian D, Alavi A.Evolving concept of imaging bone marrow metastasis in the twenty-first century:critical role of FDG-PET[J].Eur J Nucl Med Mol imaging, 2008, 35(3):465-471. doi: 10.1007/s00259-007-0593-0 [14] Adams HJA, Kwee TC, Lokhorst HM, et al.Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy[J].J Magn Reson Imaging, 2014, 39(6):1394-1400.DOI:10.1002/jmri.24318. [15] Tsunoda S, Takagi S, Tanaka O, et al.Clinical and prognostic significance of femoral marrow magnetic resonance imaging in patients with malignant lymphoma[J].Blood, 1997, 89(1):286-290. doi: 10.1182/blood.V89.1.286 [16] Ribrag V, Vanel D, Leboulleux S, et al.Prospective study of bone marrow infiltration in aggressive lymphoma by three independe nt methods:whole-body MRI, PET/CT and bone marrow biopsy[J].Eur J Radiol, 2008, 66(2):325-331.DOI:10.1016/j.ejrad.2007.06.014. [17] 闫瑾, 林祥通.PET预测及评价肿瘤疗效的新进展[J].国际放射医学核医学杂志, 2006, 30(4):214-217.
Yan J, Lin ST.The new advance of predication and advalution of tumor thera peutic effects by PET[J].Inter J Radiat Med Nucl Med, 2006, 30(4):214-217.[18] Khan AB, Barrington SF, Mikhaeel NG, et al.PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement[J].Blood, 2013, 122(1):61-67.DOI:10.1182/blood-2012-12-473389. [19] El-Galaly TC, d'Amore F, Mylam KJ et al.Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma[J].J Clin Oncol, 2012, 30(36):4508-4514.DOI:10.1200/JCO.2012.42.4036. [20] Littooij AS, Kwee TC, Barber I, et al.Whole-body MRI for initial staging of paediatric lymphoma:prospective comparison to an FDG-PET/CT-based reference standard[J].Eur Radiol, 2014, 24(5):1153-1165.DOI:10.1007/s00330-014-3114-0. [21] Ferrari1 C, Minoia C, Asabella AN, et al.Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to 18F-FDG PET/CT in newly FDG PET/CT in newly diagnosed lymphoma diagnosed lymphoma[J].Hell J Nucl Med, 2014, Suppl1:40-49. [22] Abdulqadhr G, Molin D, Astrom G, et al.Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients[J].Acta Radiol, 2011, 52(2):173-180.DOI:10.1258/ar.2010.100246. [23] Wu X, Kellokumpu-Lehtinen PL, Pertovaara H, et al.Diffusion-weighted MRI in early chemotherapy response evaluation of patientswith diffuse large B-cell lymphoma-a pilot study:comparison with 2-deoxy-2-fluoro-D-glucose-positron emission tomography/computed tomography[J].NMR Biomed, 2011, 24(10):1181-1190.DOI; 10.1002/nbm.1689. doi: 10.1002/nbm.1689 [24] Marina V, Milena R, Vesna P, et al.Complementary roles of bone scintigraphy and MR imaging in the detection and long-term follow-up of primary non-Hodgkin's bone lymphoma in a child-case report[J].Skeletal Radiol, 2015, 44(6):863-868.DOI:10.1007/s00256-014-2067-3.
计量
- 文章访问数: 3193
- HTML全文浏览量: 2054
- PDF下载量: 4